Evidence supporting the use of: Ibutamoren
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Ibutamoren (also known as MK-677) is a non-peptide agonist of the ghrelin receptor and stimulates the secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Its potential use in osteoporosis is supported by its anabolic effects on bone metabolism. Several clinical studies and trials have investigated the effects of Ibutamoren on bone mineral density (BMD) and bone turnover markers. For example, a randomized, double-blind, placebo-controlled trial published in "The Journal of Clinical Endocrinology & Metabolism" (2008) demonstrated that elderly subjects given Ibutamoren for 12 months showed increased BMD and markers of bone formation compared to placebo. The mechanism involves increased GH and IGF-1, both of which play established roles in bone growth and remodeling. However, the evidence is not yet robust enough for regulatory approval or guideline-supported clinical use in osteoporosis, as most studies have small sample sizes, short durations, and focus on surrogate markers rather than fracture outcomes. There are also concerns regarding adverse effects, such as increased appetite, edema, and possible insulin resistance. In summary, Ibutamoren’s use for osteoporosis has a moderate level of scientific support, primarily from human trials that demonstrate positive effects on bone turnover and density, but further large-scale and long-term studies are needed to confirm efficacy and safety, especially regarding reduction in fracture risk.

More about Ibutamoren
More about Osteoporosis

Products containing Ibutamoren

We currently have no products on Vitabase that contain this ingredient.